Mucopolysaccharidosis type 6 (MPS VI), also known as Maroteaux-Lamy syndrome, is a rare genetic disorder belonging to the group of mucopolysaccharidoses. This disorder results from a deficiency of the enzyme arylsulfatase B, which leads to the accumulation of glycosaminoglycans, particularly dermatan sulfate, in various tissues and organs of the body. Clinical manifestations of the disease may include systemic changes such as cardiomyopathy, motor dysfunction, and changes in appearance including facial dysplasia and shortened limbs. The likelihood of disease progression varies from patient to patient, however, there is a common factor - deterioration in quality of life and decreased life expectancy without adequate treatment.
History of the disease and interesting historical facts
Maroteaux-Lamy syndrome was first described in 1971 by Italian specialists, after which the disease became known under this nosological entity. Earlier references to mucopolysaccharidoses exist, but it was MPS VI that was identified as a separate condition thanks to the efforts of researchers studying the clinical and biochemical characteristics of the disease. Scientists have found that arylsulfatase B deficiency leads to specific pathogenetic mechanisms, which, in turn, explain the manifestations of the clinical picture. It is interesting to note that the first cases of the disease were observed in Italian families, which contributed to subsequent genetic studies.
Epidemiology
The prevalence of mucopolysaccharidosis type 6 is approximately 1 in 250,000 live births. However, depending on ethnicity and genetic background, this rate can vary significantly. According to studies, in certain populations, such as people with certain hereditary factors, the incidence of the disease can reach 1 in 100,000. Since the disease is recessive, the risk of transmitting the disease increases in families with members suffering from mucopolysaccharidoses.
Genetic predisposition to this disease
Mucopolysaccharidosis type 6 is caused by mutations in the ARSB gene located on chromosome 5. These mutations result in decreased activity of the enzyme arylsulfatase B, which directly affects the metabolism of dermatan sulfate. More than 40 different mutations in this gene are known, many of which are point substitutions, which describes the high level of heterogeneity of the disease. Deleterious mutations can be inherited in an autosomal recessive manner, which emphasizes the importance of genetic counseling for families with cases of this disease.
Risk factors for the development of this disease
Risk factors that contribute to the development of mucopolysaccharidosis type 6 include:
- Family history of the disease;
- Heredity associated with an autosomal recessive type of transmission;
- Genetic mutations in the ARSB gene;
- Uneven distribution of the disease in certain ethnic groups.
The absence of external risk factors, such as exposure to chemicals or working conditions, in this case indicates a strictly genetic nature of the disease.
Diagnosis of this disease
Diagnosis of mucopolysaccharidosis type 6 is carried out using several methods:
- Clinical examination - identification of characteristic facial features, shortening of limbs;
- Laboratory tests - determination of the level of glucosaminoglycans in urine;
- Genetic testing - detection of mutations in the ARSB gene;
- Radiological examinations - assessment of the condition of joints and bones;
- Other types of diagnostics include studying cardiovascular function and hearing assessment.
Differential diagnosis includes exclusion of other mucopolysaccharidoses, as well as diseases with similar symptoms, such as incomplete osteogenesis.
Treatment
Treatment of mucopolysaccharidosis type 6 should be comprehensive and individually tailored. It includes:
- General treatment – symptom support, working with a multidisciplinary team;
- Pharmacological treatment - use of enzyme replacement therapy;
- Surgical treatment – correction of bone deformities and other complications;
- Other treatments include physical therapy and occupational therapy to improve quality of life.
An important aspect is early diagnosis and timely initiation of treatment.
List of medications used to treat this disease
Currently, one of the promising drugs for the treatment of MPS VI is:
- Laronsidez (Elapegademase) is an enzyme replacement therapy;
- Other supportive drugs to improve the condition of joints and the cardiovascular system.
A well-chosen treatment regimen can significantly improve the quality of life of patients.
Disease monitoring
Monitoring the condition of patients with mucopolysaccharidosis type 6 includes control over the dynamics of the disease, regular examinations and correction of therapy. The main stages of monitoring:
- Regular medical examinations - assessment of functional status;
- Genetic testing - dynamics of mutation status;
- Prediction of complications – prevention and early diagnosis of concomitant diseases.
The prognosis with timely treatment is improved, although many patients may experience systemic complications.
Age-related features of the disease
Mucopolysaccharidosis type 6 manifests itself differently in different age groups:
- In newborns, signs of underdevelopment can often be observed;
- In children, various bone and joint anomalies are noticeable;
- In adults, there is an increased risk of cardiovascular disease and other systemic disorders.
The dynamics of the disease requires active monitoring at all stages of the patient's development.
Questions and Answers
- How is mucopolysaccharidosis type 6 inherited?
The disease is inherited in an autosomal recessive manner, meaning that both parents must be carriers of the mutation for their child to develop the disease. - What are the main symptoms of the disease?
The main symptoms include shortening of the limbs, specific changes in the face, and possible cardiovascular and joint problems. - How is mucopolysaccharidosis type 6 diagnosed?
Diagnosis includes clinical examination, genetic testing, and urine glucosaminoglycan testing. - What is the life expectancy of patients with MPS VI?
Life expectancy depends on the severity of the disease, but without treatment, most patients experience serious complications; with therapy, the prognosis can be significantly better. - What is the treatment for mucopolysaccharidosis type 6?
Treatment includes enzyme replacement therapy, surgery to correct deformities, and supportive care to improve quality of life.
